Cibus Therapeutics

What Cibus Therapeutics does

Cibus Therapeutics is a clinical-stage biopharmaceutical company headquartered in Stanford Research Park, Palo Alto, California, developing small-molecule therapies for gastrointestinal inflammatory diseases. Its pipeline focuses on chronic pancreatitis and ulcerative colitis, indications where it characterizes current treatment as inadequate or absent. The lead candidate CBT-248 is in Phase 1 clinical trials for chronic pancreatitis (and is also described as relevant to hereditary pancreatitis and ulcerative colitis); CBT-101 is in IND-enabling studies, targeting inflammatory pathways including the NLRP3 inflammasome, JAK/STAT, and cytokine cascades, with First-in-Human trials planned for 2026; and CBT-102 is an earlier-stage candidate for acute pancreatitis. The company frames its platform as precision modulation of multiple inflammatory pathways to address root causes of GI inflammation rather than symptom management.

The company is pre-revenue, with no commercial product, no disclosed pricing, and no enterprise customers. Its go-to-market is the standard clinical-stage biotech model: advance candidates through preclinical and clinical development, eventually commercialize via pharmaceutical supply chains and specialty pharmacy following regulatory approval, with current distribution limited to investigational therapy at clinical trial sites. The team includes co-founders Dr. Joseph C. Wu (Director of the Stanford Cardiovascular Institute) and Jade Chao (MPH/JD), with Lip-Bu Tan (Walden International, Cadence Design Systems) as Board Chair and a Scientific Advisory Board that includes former Pfizer CMO Aida Habtezion and Cedars-Sinai's Stephen Pandol. Strategic partnerships include co-developer Greenstone Biosciences and patient-advocacy ally Mission: Cure, alongside CROs and academic collaborators supporting trial execution.

Name

Cibus Therapeutics

Legal name

Cibus Therapeutics

Website

https://cibustherapeutics.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Short description

Cibus Therapeutics is a pre-revenue, clinical-stage biopharmaceutical company in Palo Alto developing small-molecule therapies for chronic pancreatitis and ulcerative colitis, with lead candidate CBT-248 in Phase 1 trials and CBT-101 in IND-enabling studies.

Ownership category

akta.pro rank

Product category

Gastrointestinal Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Gastroenterology Specialty Pharmaceuticals (HLAIACAE)

akta.pro secondary industry

Liver & GI Clinical Research (Trials Centers) (HLAKAEAL)

Keywords

• Small-molecule therapies
• Gastrointestinal disease treatments
• Chronic pancreatitis therapeutics
• Inflammatory bowel disease drugs
• Clinical-stage biopharmaceutical

Headquarters

HQ city

Palo Alto

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pharmaceutical Product Revenue: Pre-revenue clinical-stage company. Future revenue will come from commercialization of small-molecule drug therapies for chronic pancreatitis and inflammatory bowel disease following successful clinical trials and regulatory approval.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

Cibus Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of oral small-molecule therapies that modulate multiple inflammatory signaling pathways (NLRP3 inflammasome, JAK/STAT, cytokine cascades) to treat chronic pancreatitis and inflammatory bowel disease. The lead candidate CBT-248 is in Phase 1 clinical trials, CBT-101 is in IND-enabling studies with First-in-Human trials planned for 2026, and CBT-102 is in development for acute pancreatitis.

Product overview

Cibus Therapeutics is developing a pipeline of targeted small-molecule therapies for gastrointestinal inflammatory diseases. The company's core products include CBT-248 (Phase 1, chronic pancreatitis and ulcerative colitis), CBT-101 (IND-enabling, chronic pancreatitis and ulcerative colitis), and CBT-102 (acute pancreatitis). All three candidates are small-molecule drugs designed to modulate inflammatory signaling pathways, with CBT-101 specifically targeting NLRP3 inflammasome, JAK/STAT, and cytokine cascades. The products are designed as oral therapies targeting the root causes of GI inflammation rather than just managing symptoms.

Differentiator

Problem solved

Functional benefit

Products and services

• CBT-248 CBT-248 is a small-molecule therapy in Phase 1 clinical trials that modulates inflammatory signaling cascades to treat chronic pancreatitis (including hereditary pancreatitis) and ulcerative colitis, targeting the underlying mechanisms of gastrointestinal inflammation.
• CBT-101 CBT-101 is a small-molecule therapy in IND-enabling studies designed to modulate inflammatory signaling pathways including the NLRP3 inflammasome, JAK/STAT, and cytokine cascades for the treatment of chronic pancreatitis and ulcerative colitis; First-in-Human trials are planned for 2026.
• CBT-102 CBT-102 is a small-molecule therapy in development for the treatment of acute pancreatitis, extending the company's pipeline beyond chronic indications.

Quantifiable outcome

• Preclinical studies show promising reductions in inflammatory markers and tissue damage in multiple pancreatitis models
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Mission: CurecoreStrategic or Co-development Partner · 18 April 2026Mission: Cure is the only nonprofit organization solely focused on curing pancreatitis, funding innovative research and driving collaboration across academia, industry, and patient communities. Cibus Therapeutics partners with Mission: Cure to advance research and awareness for chronic pancreatitis. The company sponsored Mission: Cure's Gala event to accelerate research and improve outcomes for patients with pancreatitis.
• Greenstone BiosciencescoreStrategic or Co-development Partner · 18 April 2026Greenstone Biosciences is a biotechnology company working together with Cibus Therapeutics to develop next-generation treatments for pancreatic and gastrointestinal diseases. The partnership focuses on advancing the CBT-248 molecule for chronic pancreatitis treatment, combining complementary expertise in drug development and research.
• Leading Academic InstitutionsminorStrategic or Co-development PartnerAcademic partnerships supporting preclinical and clinical studies in gastrointestinal inflammation and fibrosis. Collaboration with academic researchers in GI inflammation or fibrosis for co-development opportunities.
• Specialized CROsminorImplementation/ SI/ Consulting PartnerPartnerships with specialized Contract Research Organizations (CROs) driving operational excellence in clinical trial execution. CRO partners support all facets of clinical development from protocol development to trial execution and data analysis.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• AbbVie: Dominant IBD franchise (Humira, Skyrizi, Rinvoq) and aggressive business development in immunology/GI. Represents both the competitive incumbent and the most likely strategic acquirer for differentiated IBD assets like Cibus's pipeline.
• Theravance Biopharma: Commercial-stage biopharma with a marketed GI product (Yuanpera) and pipeline in inflammatory GI conditions. Comparable as a small-to-mid-cap GI-focused biopharma and a relevant benchmark for capital efficiency in the space.
• Pfizer: Major IBD player with JAK inhibitors and a former Chief Medical Officer (Dr. Aida Habtezion) now on Cibus's SAB. Highly relevant incumbent competitor in JAK/STAT and a likely strategic acquirer/partner, with a direct insider connection to Cibus's leadership network.
• RedHill Biopharma: Commercial-stage specialty pharma focused on GI diseases with multiple approved products. Provides a benchmark for commercial-stage GI-focused specialty pharma and a potential late-stage comparator or acquirer.

Direct peers

• Prometheus Biosciences: Clinical-stage biotech focused on precision therapeutics for immune-mediated diseases including IBD (ulcerative colitis and Crohn's). Acquired by Merck in 2023 for ~$11B, demonstrating the strategic value of IBD-focused biotechs and serving as the closest direct comparable for Cibus's ulcerative colitis program.
• Landos Biopharma: Clinical-stage biotech developing oral small-molecule therapeutics for autoimmune diseases including ulcerative colitis. Closely aligned with Cibus in modality (oral small molecule), therapeutic area (UC), and stage of development.
• Jecure Therapeutics (acquired by Genentech/Roche): Preclinical NLRP3 inflammasome inhibitor developer acquired by Genentech in 2018. Demonstrates strategic interest in NLRP3 programs and provides another pharma-acquisition benchmark for Cibus's inflammasome-targeting pipeline.
• Inflazome (acquired by Roche): Small-molecule NLRP3 inflammasome inhibitor developer acquired by Roche in 2020. Validates pharma strategic appetite for NLRP3-targeted inflammation assets and represents the most relevant M&A benchmark for Cibus.
• Ventus Therapeutics: Clinical-stage biotech developing small-molecule therapeutics targeting the NLRP3 inflammasome and other innate immune pathways. Highly relevant direct comparable given Cibus's lead mechanism targets NLRP3 inflammasome in GI inflammation.

Emerging players

• Nimbus Therapeutics: Private biotech using structure-based drug design to develop small-molecule therapeutics across immunology, metabolic disease, and oncology. Comparable in modality (oral small molecules) and inflammation/immunology focus, though broader in indication scope.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/cibustherapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cibus Therapeutics